SCHEMBL810145

SCHEMBL810145

Cc1cccc(Sc2ccc(C)cc2Nc2ncnc3nc(SCc4ccccc4)ncc23)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.39
AKT2 P31751 1/20 0.39
MAPT P10636 3/20 0.36
ALDH1A1 P00352 2/20 0.36
RXFP1 Q9HBX9 1/20 0.35
LMNA P02545 4/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GCK P35557 2/20 0.34
POLB P06746 1/20 0.34
PKM P14618 1/20 0.34
HPGD P15428 4/20 0.34
HTT P42858 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
METAP2 P50579 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CYP1A2 P05177 1/20 0.33
ALOX15 P16050 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL811189 0.95 PIM1 (0.42) PIM1AKT2MAPTALDH1A1RXFP1
SCHEMBL810905 0.93 PIM1 (0.42) PIM1AKT2MAPTALDH1A1RXFP1
SCHEMBL811281 0.93 PIM1 (0.43) PIM1AKT2MAPTALDH1A1RXFP1
SCHEMBL810498 0.90 PIM1 (0.41) PIM1AKT2MAPTRXFP1LMNA
SCHEMBL811196 0.88 PIM1 (0.45) PIM1AKT2MAPTALDH1A1LMNA
SCHEMBL810994 0.86 PIM1 (0.40) PIM1AKT2ALDH1A1RXFP1GCK
SCHEMBL811090 0.85 LMNA (0.39) PIM1AKT2MAPTLMNAHTT
SCHEMBL810446 0.81 PIM1 (0.48) PIM1AKT2MAPTHPGDHTT
SCHEMBL5135609 0.81 MAPT (0.35) MAPTALDH1A1RXFP1LMNAL3MBTL1
SCHEMBL810146 0.81 METAP2 (0.40) PIM1AKT2MAPTALDH1A1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885MAPT 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.